Patent · US Active

Pharmaceutical composition containing silibinin

US10507197B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

TASLY PHARMACEUTICAL GROUP CO., LTD. · CN

Inventors

Naifeng Wu · Tianjin, CN
Xijun Yan · Tianjin, CN
He Sun · Shanghai, CN
Kaijing Yan · Tianjin, CN
Yonghong Zhu · Tianjin, CN
Shunnan Zhang · Tianjin, CN
Xiaolin Bai · Tianjin, CN
Yi He · Tianjin, CN
Xiaohui Ma · Tianjin, CN
Ting Li · Nanhu, CN
Lei Li · Zhengzhou, CN

Key dates

Filing date	Mar 22, 2016
Grant date	Dec 17, 2019
Priority date	—
Expiry date	Mar 22, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.